SCHEMBL2340187

SCHEMBL2340187

CN1C(=C2SC(=S)N(Cc3ccccc3)C2=O)Oc2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 10/20 0.55
▸ KMT2A Q03164 10/20 0.55
▸ SMN1; SMN2 Q16637 3/20 0.55
▸ MAPT P10636 6/20 0.53
▸ ALDH1A1 P00352 5/20 0.53
▸ MAPK1 P28482 5/20 0.53
▸ POLB P06746 4/20 0.53
▸ L3MBTL1 Q9Y468 2/20 0.53
▸ HPGD P15428 1/20 0.53
▸ LMNA P02545 2/20 0.44
▸ ALOX12 P18054 2/20 0.44
▸ RECQL P46063 2/20 0.44
▸ MCL1 Q07820 2/20 0.44
▸ TDP1 Q9NUW8 2/20 0.43
▸ FGB P02675 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ CTDSP1 Q9GZU7 2/20 0.42
▸ KAT2B Q92831 4/20 0.42
▸ EP300 Q09472 3/20 0.42
▸ CREBBP Q92793 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2340185 1.00 MEN1 (0.55) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL11881517 0.88 MEN1 (0.64) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL11881513 0.88 MEN1 (0.64) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL9192992 0.85 APEX1 (0.57) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL9192996 0.85 APEX1 (0.57) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL9637053 0.81 MEN1 (0.52) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL9637056 0.81 MEN1 (0.52) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL10623018 0.79 MEN1 (0.57) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL10036075 0.79 MEN1 (0.57) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL10623015 0.79 MEN1 (0.57) MEN1KMT2ASMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1465882-B1 HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-08-24 — — EP disclosed
US-7115640-B2 Heterocyclic modulators of nuclear receptors X-CEPTOR THERAPEUTICS, INC. (US) 2006-10-03 — — US disclosed
EP-1465882-A4 HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2005-04-06 — — EP disclosed
EP-1465882-A2 HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X-Ceptor Therapeutics, Inc. (US) 2004-10-13 — — EP disclosed
US-20040180942-A1 Heterocyclic modulators of nuclear receptors X-CEPTOR THERAPEUTICS, INC. 2004-09-16 — — US disclosed
US-6696473-B2 THIAZOLIDINONE DERIVATIVES; MODULATING CHOLESTEROL METABOLISM X-CEPTOR THERAPEUTICS, INC. 2004-02-24 — — US disclosed
WO-2003060078-A9 HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2004-02-19 — — WO disclosed
US-20030212111-A1 Heterocyclic modulators of nuclear receptors AKARNA THERAPEUTICS, LTD. (GB) 2003-11-13 — — US disclosed
WO-2003060078-A2 HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X-CEPTOR THERAPEUTICS, INC. (US) 2003-07-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180942-A1 Heterocyclic modulators of nuclear receptors NR1H2, NR1H3, NR1H4 MEN1 4537/4885KMT2A 2838/4885SMN1; SMN2 4858/4885
US-20030212111-A1 Heterocyclic modulators of nuclear receptors NR1H2, NR1H3, NR1H4 MEN1 4537/4885KMT2A 2838/4885SMN1; SMN2 4858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback